nach oben

Clinical and Translational Oncology

Erschienen in:

01.10.2014 | Educational Series – Blue Series

New biological markers in the decision of treatment of head and neck cancer patients

verfasst von: A. Valenciano, L. A. Henríquez-Hernández, M. Lloret, B. Pinar, P. C. Lara

Erschienen in: Clinical and Translational Oncology | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Head and neck squamous cell carcinoma is the sixth most common cancer type worldwide. Also the 5-year survival rate of less than 50 % seems to be lower than other cancer types. There are some reasons behind this high mortality rate; one of them is the lack of knowledge about the biology and genomic instability behind the carcinogenic processes. These biological features could condition the failure of frontline treatment, in which case rescue treatment should be used, representing an overtreatment for the patients. For years many biological factors have been tested as prognostic and predictive factors in relation to treatment with a modest success. To find appropriate tests which could be used in the context of the individualized treatment decision, we have reviewed new biological markers, not only in tumor tissue, but also in normal tissue from head and neck carcinoma patients.

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.PubMedCrossRef

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. doi:10.3322/caac.20138.PubMedCrossRef

Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med. 2001;345(26):1890–900. doi:10.1056/NEJMra001375.PubMedCrossRef

Chang PH, Yeh KY, Huang JS, Lai CH, Wu TH, Lan YJ, et al. Pretreatment performance status and nutrition are associated with early mortality of locally advanced head and neck cancer patients undergoing concurrent chemoradiation. Eur Arch Oto Rhino Laryngol Off J Eur Fed Oto Rhino Laryngol Soc. 2013;270(6):1909–15. doi:10.1007/s00405-012-2290-2.CrossRef

Mao L, Hong WK, Papadimitrakopoulou VA. Focus on head and neck cancer. Cancer Cell. 2004;5(4):311–6.PubMedCrossRef

Sudbo J, Lippman SM, Lee JJ, Mao L, Kildal W, Sudbo A, et al. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med. 2004;350(14):1405–13. doi:10.1056/NEJMoa033374.PubMedCrossRef

Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med. 1995;332(11):712–7. doi:10.1056/NEJM199503163321104.PubMedCrossRef

Wittekindt C, Wagner S, Mayer CS, Klussmann JP. Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer. GMS Curr Topics Otorhinolaryngol Head Neck Surg. 2012;11. doi:10.3205/cto000091.

Trivedi NP, Swaminathan DK, Thankappan K, Chatni S, Kuriakose MA, Iyer S. Comparison of quality of life in advanced laryngeal cancer patients after concurrent chemoradiotherapy vs total laryngectomy. Otolaryngol Head Neck Surg Off J Am Acad Otolaryngol Head Neck Surg. 2008;139(5):702–7. doi:10.1016/j.otohns.2008.06.002.CrossRef

10.

Lavaf A, Genden EM, Cesaretti JA, Packer S, Kao J. Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma. Cancer. 2008;112(3):535–43. doi:10.1002/cncr.23206.PubMedCrossRef

11.

Ganly I, Patel SG, Matsuo J, Singh B, Kraus DH, Boyle JO, et al. Results of surgical salvage after failure of definitive radiation therapy for early-stage squamous cell carcinoma of the glottic larynx. Arch Otolaryngol Head Neck Surg. 2006;132(1):59–66. doi:10.1001/archotol.132.1.59.PubMedCrossRef

12.

Pignon JP, le Maitre A, Maillard E, Bourhis J, Group M-NC. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2009;92(1):4–14. doi:10.1016/j.radonc.2009.04.014.CrossRef

13.

Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937–44. doi:10.1056/NEJMoa032646.PubMedCrossRef

14.

Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945–52. doi:10.1056/NEJMoa032641.PubMedCrossRef

15.

Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–8. doi:10.1016/S1470-2045(09)70311-0.PubMedCrossRef

16.

Oliveira LR, Ribeiro-Silva A. Prognostic significance of immunohistochemical biomarkers in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2011;40(3):298–307. doi:10.1016/j.ijom.2010.12.003.PubMedCrossRef

17.

Grimminger CM, Danenberg PV. Update of prognostic and predictive biomarkers in oropharyngeal squamous cell carcinoma: a review. Eur Arch Oto Rhino Laryngol Off J Eur Fed Oto Rhino Laryngol Soc. 2011;268(1):5–16. doi:10.1007/s00405-010-1369-x.CrossRef

18.

Lionello M, Staffieri A, Marioni G. Potential prognostic and therapeutic role for angiogenesis markers in laryngeal carcinoma. Acta Otolaryngol. 2012;132(6):574–82. doi:10.3109/00016489.2011.652308.PubMedCrossRef

19.

Valenciano A, Henriquez-Hernandez LA, Moreno M, Lloret M, Lara PC. Role of IGF-1 receptor in radiation response. Transl Oncol. 2012;5(1):1–9.PubMedCrossRefPubMedCentral

20.

Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 1997;57(15):3079–83.PubMed

21.

Yuan Y, Zhou X, Song J, Qiu X, Li J, Ye L, et al. Expression and clinical significance of epidermal growth factor receptor and type 1 insulin-like growth factor receptor in nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol. 2008;117(3):192–200.PubMed

22.

Taunk NK, Goyal S, Moran MS, Yang Q, Parikh R, Haffty BG. Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2010;96(2):204–8. doi:10.1016/j.radonc.2010.03.009.CrossRef

23.

Lloret M, Lara PC, Bordon E, Pinar B, Rey A, Falcon O, et al. IGF-1R expression in localized cervical carcinoma patients treated by radiochemotherapy. Gynecol Oncol. 2007;106(1):8–11. doi:10.1016/j.ygyno.2007.04.004.PubMedCrossRef

24.

Geoerger B, Brasme JF, Daudigeos-Dubus E, Opolon P, Venot C, Debussche L, et al. Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma. Eur J Cancer. 2010;46(18):3251–62. doi:10.1016/j.ejca.2010.06.005.PubMedCrossRef

25.

Chang CH, Wang Y, Trisal P, Li R, Rossi DL, Nair A, et al. Evaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell lines. PLoS ONE. 2012;7(8):e44235. doi:10.1371/journal.pone.0044235.PubMedCrossRefPubMedCentral

26.

Wojtalla A, Salm F, Christiansen DG, Cremona T, Cwiek P, Shalaby T, et al. Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma. PLoS ONE. 2012;7(10):e47109. doi:10.1371/journal.pone.0047109.PubMedCrossRefPubMedCentral

27.

Lara PC, Bordon E, Rey A, Moreno M, Lloret M, Henriquez-Hernandez LA. IGF-1R expression predicts clinical outcome in patients with locally advanced oral squamous cell carcinoma. Oral Oncol. 2011;47(7):615–9. doi:10.1016/j.oraloncology.2011.05.005.PubMedCrossRef

28.

Moeller BJ, Yordy JS, Williams MD, Giri U, Raju U, Molkentine DP, et al. DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(7):2035–43. doi:10.1158/1078-0432.CCR-10-2641.CrossRef

29.

Pavon MA, Parreno M, Leon X, Sancho FJ, Cespedes MV, Casanova I, et al. Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer. Int J Cancer J Int Cancer. 2008;123(5):1068–79. doi:10.1002/ijc.23635.CrossRef

30.

Kedersha NL, Heuser JE, Chugani DC, Rome LH. Vaults. III. Vault ribonucleoprotein particles open into flower-like structures with octagonal symmetry. J Cell Biol. 1991;112(2):225–35.PubMedCrossRef

31.

Kickhoefer VA, Siva AC, Kedersha NL, Inman EM, Ruland C, Streuli M, et al. The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J Cell Biol. 1999;146(5):917–28.PubMedCrossRefPubMedCentral

32.

Kickhoefer VA, Stephen AG, Harrington L, Robinson MO, Rome LH. Vaults and telomerase share a common subunit, TEP1. J Biol Chem. 1999;274(46):32712–7.PubMedCrossRef

33.

Kedersha NL, Rome LH. Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J Cell Biol. 1986;103(3):699–709.PubMedCrossRef

34.

Silva P, West CM, Slevin N, Valentine H, Ryder WD, Hampson L, et al. Tumor expression of major vault protein is an adverse prognostic factor for radiotherapy outcome in oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007;69(1):133–40. doi:10.1016/j.ijrobp.2007.02.025.PubMedCrossRef

35.

Lara PC, Pruschy M, Zimmermann M, Henriquez-Hernandez LA. MVP and vaults: a role in the radiation response. Radiat Oncol. 2011;6:148. doi:10.1186/1748-717X-6-148.PubMedCrossRefPubMedCentral

36.

Lloret M, Lara PC, Bordon E, Fontes F, Rey A, Pinar B, et al. Major vault protein may affect nonhomologous end-joining repair and apoptosis through Ku70/80 and bax downregulation in cervical carcinoma tumors. Int J Radiat Oncol Biol Phys. 2009;73(4):976–9. doi:10.1016/j.ijrobp.2008.11.013.PubMedCrossRef

37.

Henriquez-Hernandez LA, Moreno M, Rey A, Lloret M, Lara PC. MVP expression in the prediction of clinical outcome of locally advanced oral squamous cell carcinoma patients treated with radiotherapy. Radiat Oncol. 2012;7:147. doi:10.1186/1748-717X-7-147.PubMedCrossRefPubMedCentral

38.

Junttila MR, Ala-Aho R, Jokilehto T, Peltonen J, Kallajoki M, Grenman R, et al. p38alpha and p38delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Oncogene. 2007;26(36):5267–79. doi:10.1038/sj.onc.1210332.PubMedCrossRef

39.

Gill K, Mohanti BK, Ashraf MS, Singh AK, Dey S. Quantification of p38alphaMAP kinase: a prognostic marker in HNSCC with respect to radiation therapy. Clin Chim Acta Int J Clin Chem. 2012;413(1–2):219–25. doi:10.1016/j.cca.2011.09.031.CrossRef

40.

Dutra RL, de Carvalho MB, Dos Santos M, Mercante AM, Gazito D, de Cicco R, et al. FGFR4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx. PLoS ONE. 2012;7(11):e50747. doi:10.1371/journal.pone.0050747.PubMedCrossRefPubMedCentral

41.

Tse KP, Tsang NM, Chen KD, Li HP, Liang Y, Hsueh C, et al. MCP-1 Promoter Polymorphism at 2518 is associated with metastasis of nasopharyngeal carcinoma after treatment. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(21):6320–6. doi:10.1158/1078-0432.CCR-07-1029.CrossRef

42.

Tu HF, Chen HW, Kao SY, Lin SC, Liu CJ, Chang KW. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2008;87(2):243–52. doi:10.1016/j.radonc.2008.03.018.CrossRef

43.

Munoz-Guerra MF, Fernandez-Contreras ME, Moreno AL, Martin ID, Herraez B, Gamallo C. Polymorphisms in the hypoxia inducible factor 1-alpha and the impact on the prognosis of early stages of oral cancer. Ann Surg Oncol. 2009;16(8):2351–8. doi:10.1245/s10434-009-0503-8.PubMedCrossRef

44.

Carles J, Monzo M, Amat M, Jansa S, Artells R, Navarro A, et al. Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006;66(4):1022–30. doi:10.1016/j.ijrobp.2006.06.029.PubMedCrossRef

45.

Vivenza D, Gasco M, Monteverde M, Lattanzio L, Syed N, Colantonio I, et al. MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer. Oral Oncol. 2012;48(7):602–7. doi:10.1016/j.oraloncology.2012.01.022.PubMedCrossRef

46.

Supic G, Jovic N, Zeljic K, Kozomara R, Magic Z. Association of VEGF-A genetic polymorphisms with cancer risk and survival in advanced-stage oral squamous cell carcinoma patients. Oral Oncol. 2012;48(11):1171–7. doi:10.1016/j.oraloncology.2012.05.023.PubMedCrossRef

47.

Xie X, Wang H, Jin H, Ouyang S, Zhou J, Hu J, et al. Expression of pAkt affects p53 codon 72 polymorphism-based prediction of response to radiotherapy in nasopharyngeal carcinoma. Radiat Oncol. 2013;8:117. doi:10.1186/1748-717X-8-117.PubMedCrossRefPubMedCentral

48.

Bentzen SM, Overgaard J. Patient-to-patient variability in the expression of radiation-induced normal tissue injury. Semin Radiat Oncol. 1994;4(2):68–80. doi:10.1053/SRAO00400068.PubMedCrossRef

49.

Azria D, Ozsahin M, Kramar A, Peters S, Atencio DP, Crompton NE, et al. Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14(19):6284–8. doi:10.1158/1078-0432.CCR-08-0700.CrossRef

50.

Azria D, Betz M, Bourgier C, Jeanneret Sozzi W, Ozsahin M. Identifying patients at risk for late radiation-induced toxicity. Crit Rev Oncol Hematol. 2012;84:e35–41. doi:10.1016/j.critrevonc.2010.08.003.PubMedCrossRef

51.

Russell NS, Lara PC, Grummels A, Hart AA, Coco-Martin JM, Bartelink H, et al. In vitro differentiation characteristics of human skin fibroblasts: correlations with radiotherapy-induced breast fibrosis in patients. Int J Radiat Biol. 2000;76(2):231–40.PubMedCrossRef

52.

Oppitz U, Baier K, Wulf J, Schakowski R, Flentje M. The in vitro colony assay: a predictor of clinical outcome. Int J Radiat Biol. 2001;77(1):105–10.PubMedCrossRef

53.

Bordon E, Henriquez-Hernandez LA, Lara PC, Ruiz A, Pinar B, Rodriguez-Gallego C, et al. Prediction of clinical toxicity in locally advanced head and neck cancer patients by radio-induced apoptosis in peripheral blood lymphocytes (PBLs). Radiat Oncol. 2010;5:4. doi:10.1186/1748-717X-5-4.PubMedCrossRefPubMedCentral

54.

Ozsahin M, Ozsahin H, Shi Y, Larsson B, Wurgler FE, Crompton NE. Rapid assay of intrinsic radiosensitivity based on apoptosis in human CD4 and CD8 T-lymphocytes. Int J Radiat Oncol Biol Phys. 1997;38(2):429–40.PubMedCrossRef

55.

Ozsahin M, Crompton NE, Gourgou S, Kramar A, Li L, Shi Y, et al. CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: a prospective study in 399 patients. Clin Cancer Res. 2005;11(20):7426–33. doi:10.1158/1078-0432.CCR-04-2634.PubMedCrossRef

56.

Bordon E, Henriquez Hernandez LA, Lara PC, Pinar B, Fontes F, Rodriguez Gallego C et al. Prediction of clinical toxicity in localized cervical carcinoma by radio-induced apoptosis study in peripheral blood lymphocytes (PBLs). Radiation oncology. 2009;4:58. doi:10.1186/1748-717X-4-58.

57.

Alapetite C, Thirion P, de la Rochefordiere A, Cosset JM, Moustacchi E. Analysis by alkaline comet assay of cancer patients with severe reactions to radiotherapy: defective rejoining of radioinduced DNA strand breaks in lymphocytes of breast cancer patients. Int J Cancer J Int Cancer. 1999;83(1):83–90.CrossRef

58.

Pinar B, Lara PC, Lloret M, Bordon E, Nunez MI, Villalobos M, et al. Radiation-induced DNA damage as a predictor of long-term toxicity in locally advanced breast cancer patients treated with high-dose hyperfractionated radical radiotherapy. Radiat Res. 2007;168(4):415–22. doi:10.1667/RR0746.1.PubMedCrossRef

59.

Goutham HV, Mumbrekar KD, Vadhiraja BM, Fernandes DJ, Sharan K, Kanive Parashiva G, et al. DNA double-strand break analysis by gamma-H2AX foci: a useful method for determining the overreactors to radiation-induced acute reactions among head-and-neck cancer patients. Int J Radiat Oncol Biol Phys. 2012;84(5):e607–12. doi:10.1016/j.ijrobp.2012.06.041.PubMedCrossRef

60.

El-Naggar AK, Kim HW, Clayman GL, Coombes MM, Le B, Lai S, et al. Differential expression profiling of head and neck squamous carcinoma: significance in their phenotypic and biological classification. Oncogene. 2002;21(53):8206–19. doi:10.1038/sj.onc.1206021.PubMedCrossRef

61.

Mendez E, Houck JR, Doody DR, Fan W, Lohavanichbutr P, Rue TC, et al. A genetic expression profile associated with oral cancer identifies a group of patients at high risk of poor survival. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(4):1353–61. doi:10.1158/1078-0432.CCR-08-1816.CrossRef

62.

Thurlow JK, Pena Murillo CL, Hunter KD, Buffa FM, Patiar S, Betts G, et al. Spectral clustering of microarray data elucidates the roles of microenvironment remodeling and immune responses in survival of head and neck squamous cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(17):2881–8. doi:10.1200/JCO.2009.24.8724.CrossRef

63.

Hanna E, Shrieve DC, Ratanatharathorn V, Xia X, Breau R, Suen J, et al. A novel alternative approach for prediction of radiation response of squamous cell carcinoma of head and neck. Cancer Res. 2001;61(6):2376–80.PubMed

64.

Quarmby S, West C, Magee B, Stewart A, Hunter R, Kumar S. Differential expression of cytokine genes in fibroblasts derived from skin biopsies of patients who developed minimal or severe normal tissue damage after radiotherapy. Radiat Res. 2002;157(3):243–8.PubMedCrossRef

65.

Henriquez Hernandez LA, Lara PC, Pinar B, Bordon E, Rodriguez Gallego C, Bilbao C, et al. Constitutive gene expression profile segregates toxicity in locally advanced breast cancer patients treated with high-dose hyperfractionated radical radiotherapy. Radiat Oncol. 2009;4:17. doi:10.1186/1748-717X-4-17.PubMedCrossRefPubMedCentral

66.

Mayer C, Popanda O, Greve B, Fritz E, Illig T, Eckardt-Schupp F, et al. A radiation-induced gene expression signature as a tool to predict acute radiotherapy-induced adverse side effects. Cancer Lett. 2011;302(1):20–8. doi:10.1016/j.canlet.2010.12.006.PubMedCrossRef

67.

Lunde ML, Warnakulasuriya S, Sand L, Hirsch JM, Vasstrand EN, Ibrahim SO. Gene expression analysis by cDNA microarray in oral cancers from two Western populations. Anticancer Res. 2010;30(4):1083–91.PubMed

68.

Henriquez-Hernandez LA, Pinar B, Carmona-Vigo R, Bordon E, Rodriguez-Gallego C, Flores-Morales A, et al. Common genomic signaling among initial DNA damage and radiation-induced apoptosis in peripheral blood lymphocytes from locally advanced breast cancer patients. Breast. 2013;22(1):28–33. doi:10.1016/j.breast.2012.05.005.PubMedCrossRef

69.

Popanda O, Marquardt JU, Chang-Claude J, Schmezer P. Genetic variation in normal tissue toxicity induced by ionizing radiation. Mutat Res. 2009;667(1–2):58–69. doi:10.1016/j.mrfmmm.2008.10.014.PubMedCrossRef

70.

Barnett GC, Coles CE, Elliott RM, Baynes C, Luccarini C, Conroy D, et al. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol. 2012;13(1):65–77. doi:10.1016/S1470-2045(11)70302-3.PubMedCrossRef

71.

Ghazali N, Shaw RJ, Rogers SN, Risk JM. Genomic determinants of normal tissue toxicity after radiotherapy for head and neck malignancy: a systematic review. Oral Oncol. 2012;48(11):1090–100. doi:10.1016/j.oraloncology.2012.08.002.PubMedCrossRef

72.

West C, Rosenstein BS, Alsner J, Azria D, Barnett G, Begg A, et al. Establishment of a Radiogenomics Consortium. Int J Radiat Oncol Biol Phys. 2010;76(5):1295–6. doi:10.1016/j.ijrobp.2009.12.017.PubMedCrossRef

73.

Bhatnagar R, Dabholkar J, Saranath D. Genome-wide disease association study in chewing tobacco associated oral cancers. Oral Oncol. 2012;48(9):831–5. doi:10.1016/j.oraloncology.2012.03.007.PubMedCrossRef

Titel: New biological markers in the decision of treatment of head and neck cancer patients
verfasst von: A. Valenciano
L. A. Henríquez-Hernández
M. Lloret
B. Pinar
P. C. Lara
Publikationsdatum: 01.10.2014
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 10/2014
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-014-1193-7

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

New biological markers in the decision of treatment of head and neck cancer patients

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2014

Bevacizumab in advanced cervical cancer

Aldehyde dehydrogenases in early stage lung cancer: nuclear expression

Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana’s predictive model

Looking for complementary alternatives to CTCAE for skin toxicity in radiotherapy: quantitative determinations

Second primary malignancies in patients with neuroendocrine tumors

Subcutaneous trastuzumab: drug development and current position

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie